Opiant Pharmaceuticals, Inc. (OPNT)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Opiant Pharmaceuticals, Inc. (OPNT) with AI Score 60/100 (Hold). Opiant Pharmaceuticals, Inc. develops and commercializes treatments for addictions and drug overdose, with a primary focus on opioid overdose reversal. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Opiant Pharmaceuticals, Inc. (OPNT) Healthcare & Pipeline Overview
Opiant Pharmaceuticals, Inc. specializes in developing and marketing treatments for addictions and overdoses, primarily known for NARCAN nasal spray, an opioid overdose reversal medication. With a focus on addressing critical public health needs, Opiant operates within the biotechnology sector, holding a market capitalization of $0.11 billion.
Investment Thesis
Opiant Pharmaceuticals, Inc. presents a focused investment opportunity within the biotechnology sector, driven by its established presence in the opioid overdose reversal market with NARCAN nasal spray. The company's consistent gross margin of 77.7% indicates strong pricing power and efficient operations. Growth catalysts include the potential approval and commercialization of pipeline products targeting alcohol use disorders and cannabinoid overdose. However, investors may want to evaluate the company's relatively small market capitalization of $0.11 billion and the competitive landscape, including generic alternatives to NARCAN. The company's P/E ratio of 30.58 reflects market expectations of future growth, which must be balanced against execution risks in clinical development and regulatory approvals.
Based on FMP financials and quantitative analysis
Key Highlights
- NARCAN Nasal Spray: Opiant's flagship product, a widely recognized treatment for opioid overdose reversal.
- Gross Margin of 77.7%: Demonstrates strong pricing power and efficient cost management in the pharmaceutical market.
- Market Capitalization of $0.11 Billion: Indicates a smaller-cap company with potential for growth but also higher volatility.
- Profit Margin of 7.4%: Reflects profitability in a competitive pharmaceutical landscape.
- Pipeline of Product Candidates: Includes treatments for alcohol use disorders, acute cannabinoid overdose, and opioid use disorders, offering potential future revenue streams.
Competitors & Peers
Strengths
- Established product with NARCAN nasal spray.
- High gross margin indicates strong pricing power.
- Pipeline of product candidates targeting various addiction-related disorders.
- Experienced management team focused on addiction treatment.
Weaknesses
- Reliance on a single product for revenue.
- Small market capitalization increases volatility.
- Dependence on regulatory approvals for pipeline products.
- Competition from generic alternatives to NARCAN.
Catalysts
- Regulatory decisions on pipeline products targeting alcohol use disorders.
- Expansion of NARCAN nasal spray distribution through partnerships with public health organizations.
- Clinical trial results for new formulations of existing drugs.
- Potential acquisitions or licensing agreements to expand product portfolio.
Risks
- Competition from generic alternatives to NARCAN nasal spray.
- Regulatory delays or unfavorable decisions regarding pipeline products.
- Dependence on a single product for the majority of revenue.
- Product liability claims related to opioid overdose reversal treatments.
Growth Opportunities
- Expansion of NARCAN Nasal Spray Market: Opiant can expand the market for NARCAN by increasing accessibility and distribution channels, including partnerships with public health organizations and community groups. The opioid crisis continues to drive demand, with a market size estimated to reach billions of dollars. Timeline: Ongoing.
- Development and Commercialization of Alcohol Use Disorder Treatment: Opiant's pipeline includes treatments for alcohol use disorders, representing a significant market opportunity. Alcohol use disorders affect millions of people worldwide, creating a substantial demand for effective medications. Successful development and commercialization could diversify Opiant's revenue streams. Timeline: 3-5 years.
- Treatment for Acute Cannabinoid Overdose: As cannabis legalization expands, the incidence of acute cannabinoid overdose may increase, creating a market for targeted treatments. Opiant's research in this area positions it to address an emerging medical need. Timeline: 2-4 years.
- New Formulations and Delivery Systems for Existing Drugs: Opiant can innovate by developing new formulations and delivery systems for its existing drugs, such as NARCAN. This could include longer-lasting formulations or alternative routes of administration, improving patient compliance and expanding market share. Timeline: 2-3 years.
- Strategic Partnerships and Acquisitions: Opiant can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other pharmaceutical companies or acquiring complementary technologies can accelerate growth and diversify risk. Timeline: Ongoing.
Opportunities
- Expansion of NARCAN market through increased accessibility.
- Commercialization of pipeline products for alcohol use disorders and cannabinoid overdose.
- Strategic partnerships and acquisitions to expand product portfolio.
- Development of new formulations and delivery systems.
Threats
- Competition from generic drug manufacturers.
- Regulatory challenges and delays in product approvals.
- Changes in healthcare policies and reimbursement rates.
- Product liability and litigation risks.
Competitive Advantages
- Established brand recognition with NARCAN nasal spray.
- Proprietary formulations and delivery systems.
- Strong relationships with distributors and healthcare providers.
- Focus on a specialized market with high barriers to entry.
About OPNT
Opiant Pharmaceuticals, Inc., founded in 2005 and headquartered in Santa Monica, California, is a specialty pharmaceutical company dedicated to developing treatments for addictions and drug overdose. Originally incorporated as Lightlake Therapeutics Inc., the company rebranded to Opiant Pharmaceuticals, Inc. in January 2016, signaling a refined focus on addressing the opioid crisis and related addiction challenges. The company's flagship product, NARCAN nasal spray, is a widely recognized and essential tool for reversing opioid overdoses, providing a critical intervention in emergency situations. Beyond NARCAN, Opiant maintains a pipeline of product candidates targeting various addiction-related disorders, including treatments for alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. Opiant's commitment to innovation and addressing unmet medical needs in the addiction space positions it as a key player in the biotechnology sector, with a focus on developing accessible and effective treatments for vulnerable populations.
What They Do
- Develop medicines for addictions and drug overdose.
- Offer NARCAN nasal spray, a treatment to reverse opioid overdoses.
- Focus on treatments for opioid overdose reversal.
- Develop treatments for alcohol use disorders.
- Develop treatments for acute cannabinoid overdose.
- Research treatments for opioid use disorders.
Business Model
- Develop and commercialize pharmaceutical products targeting addictions and drug overdose.
- Generate revenue through sales of NARCAN nasal spray.
- Invest in research and development to expand product pipeline.
- Partner with distributors and healthcare providers to increase market access.
Industry Context
Opiant Pharmaceuticals operates within the biotechnology industry, specifically focusing on addiction and overdose treatments. The market for opioid overdose reversal medications is driven by the ongoing opioid crisis in the United States and globally. The competitive landscape includes companies developing alternative overdose treatments and generic versions of existing medications. The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and the potential for significant revenue generation from successful products. Opiant's focus on addressing addiction-related disorders positions it within a growing segment of the healthcare market.
Key Customers
- Hospitals and emergency medical services.
- Pharmacies and retail drug stores.
- Public health organizations and government agencies.
- Individuals at risk of opioid overdose and their caregivers.
Financials
Chart & Info
Opiant Pharmaceuticals, Inc. (OPNT) stock price: Price data unavailable
Latest News
-
Earnings Scheduled For May 10, 2022
benzinga · May 10, 2022
-
Earnings Scheduled For March 15, 2022
benzinga · Mar 15, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OPNT.
Price Targets
Wall Street price target analysis for OPNT.
MoonshotScore
What does this score mean?
The MoonshotScore rates OPNT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Roger Crystal
CEO
Roger Crystal serves as the CEO of Opiant Pharmaceuticals, Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on commercial strategy and product development. Prior to joining Opiant, he held leadership positions at several pharmaceutical companies, where he was responsible for driving revenue growth and market expansion. He holds an MD from University College London.
Track Record: Under Roger Crystal's leadership, Opiant Pharmaceuticals has focused on expanding the market reach of NARCAN nasal spray and advancing its pipeline of product candidates. He has overseen the company's efforts to address the opioid crisis and develop innovative treatments for addiction-related disorders. His strategic decisions have contributed to the company's growth and market position.
Opiant Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What does Opiant Pharmaceuticals, Inc. do?
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for addictions and drug overdose. Their primary product, NARCAN nasal spray, is a life-saving medication used to reverse opioid overdoses. The company also has a pipeline of product candidates targeting alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. Opiant's mission is to address critical public health needs by providing accessible and effective treatments for vulnerable populations.
What do analysts say about OPNT stock?
Analyst coverage of Opiant Pharmaceuticals, Inc. typically focuses on the company's growth prospects in the opioid overdose reversal market and the potential of its pipeline products. Key valuation metrics include revenue growth, gross margin, and earnings per share. Analysts consider the competitive landscape, regulatory risks, and the company's ability to execute its development and commercialization strategies. The consensus view reflects expectations for future growth, balanced against the inherent risks in the biotechnology sector. No buy or sell recommendations are made.
What are the main risks for OPNT?
The main risks for Opiant Pharmaceuticals, Inc. include competition from generic alternatives to NARCAN nasal spray, which could erode market share and pricing power. Regulatory delays or unfavorable decisions regarding pipeline products could impact future revenue streams. The company's dependence on a single product for the majority of its revenue creates vulnerability. Additionally, product liability claims related to opioid overdose reversal treatments pose a potential financial risk. These factors could affect Opiant's financial performance and stock valuation.
What are the key factors to evaluate for OPNT?
Opiant Pharmaceuticals, Inc. (OPNT) currently holds an AI score of 60/100, indicating moderate score. Key strength: Established product with NARCAN nasal spray. Primary risk to monitor: Competition from generic alternatives to NARCAN nasal spray. This is not financial advice.
How frequently does OPNT data refresh on this page?
OPNT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven OPNT's recent stock price performance?
Recent price movement in Opiant Pharmaceuticals, Inc. (OPNT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established product with NARCAN nasal spray. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider OPNT overvalued or undervalued right now?
Determining whether Opiant Pharmaceuticals, Inc. (OPNT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying OPNT?
Before investing in Opiant Pharmaceuticals, Inc. (OPNT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of the latest available reporting period.